应用皮肤试验抑制指数评价抗组胺药物的疗效

Inhibition of Skin Test by Astemizole

为评价抗组胺药的疗效,建立皮肤试验抑制指数(STII)及其测定方法。选20例花粉症患者,服用息斯敏10mg q.d.连用7d,服药前、后进行皮肤滴定试验,发现本品对皮试有明显抑制作用,其STII为91。另一组花粉症患者(6人)按上法服息斯敏连用10d,于服药第5天,第10天,停药后第7天,第14天和第21天测STII,其结果分別为12,108,90,10和7,结果提示息斯敏是一种作用持久的抗组胺药。

For the purpose of evaluating the curative effect of antihistamines, we have set up an assay method called the 'Skin Test Inhibition Index'(STII).Twenty cases of hay fever were selected for astemizole administration, 10mg/d for 7 days. Skin titration test were carried out before and after treatment. Significant inhibition of skin test by astemizole was found with STII 91. Another group of 6 hay fever patients was given astemizole 10mg/d for 10 days. STII was determined on the 5th and 10th days and also on the 7th, 14th and 21st days after treatment. STII were 12, 108, 90, 10 and 7 respectively. These results clearly demonstrated that astemizole is a long-acting antihistamin.